3B Blackbio DX Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 6, 2026, 3:25 am

Market Cap	1,076 Cr.
Current Price	1,253
Intrinsic Value	₹1,104.31
High / Low	2,020/1,151
Stock P/E	18.7
Book Value	347
Dividend Yield	0.32 %
ROCE	25.8 %
ROE	19.4 %
Face Value	10.0
PEG Ratio	2.01

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for 3B Blackbio DX Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
3B Blackbio DX Ltd	1,076 Cr.	1,253	2,020/1,151	18.7	347	0.32 %	25.8 %	19.4 %	10.0
Excel Industries Ltd	1,120 Cr.	891	1,440/833	14.8	1,438	1.54 %	7.11 %	5.21 %	5.00
Meghmani Organics Ltd	1,226 Cr.	48.2	106/47.9	30.3	60.6	0.00 %	3.39 %	0.80 %	1.00
Punjab Chemicals & Crop Protection Ltd	1,315 Cr.	1,073	1,666/771	20.5	326	0.28 %	15.3 %	12.0 %	10.0
Dharmaj Crop Guard Ltd	795 Cr.	235	391/171	16.5	131	0.00 %	12.0 %	9.28 %	10.0
Industry Average	9,974.35 Cr	1,046.17		26.51	369.00	0.51%	15.21%	19.87%	6.67

All Competitor Stocks of 3B Blackbio DX Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	15	18	14	19	18	23	19	29	25	22	22	34	50
Expenses	7	11	8	11	9	13	8	13	10	15	10	19	29
Operating Profit	7	7	6	8	9	10	11	16	15	8	12	15	22
OPM %	50%	41%	45%	41%	50%	43%	56%	55%	59%	35%	53%	43%	43%
Other Income	3	1	3	3	3	4	4	3	3	5	4	6	6
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0	0	1	0
Profit before tax	10	8	9	10	11	14	14	19	18	13	16	20	27
Tax %	22%	38%	22%	26%	24%	36%	21%	23%	24%	36%	20%	23%	16%
Net Profit	8	5	7	8	9	9	11	15	13	8	13	15	22
EPS in Rs	8.96	7.72	9.71	10.46	10.16	10.33	12.97	17.07	15.61	9.79	14.67	17.14	25.32

Last Updated: March 3, 2026, 1:42 pm

Below is a detailed analysis of the quarterly data for 3B Blackbio DX Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

For Sales, as of Dec 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Sep 2025) to 50.00 Cr., marking an increase of 16.00 Cr..
For Expenses, as of Dec 2025, the value is 29.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Sep 2025) to 29.00 Cr., marking an increase of 10.00 Cr..
For Operating Profit, as of Dec 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Sep 2025) to 22.00 Cr., marking an increase of 7.00 Cr..
For OPM %, as of Dec 2025, the value is 43.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 43.00%.
For Other Income, as of Dec 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 6.00 Cr..
For Interest, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
For Depreciation, as of Dec 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Sep 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
For Profit before tax, as of Dec 2025, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Sep 2025) to 27.00 Cr., marking an increase of 7.00 Cr..
For Tax %, as of Dec 2025, the value is 16.00%. The value appears to be improving (decreasing) as expected. It has decreased from 23.00% (Sep 2025) to 16.00%, marking a decrease of 7.00%.
For Net Profit, as of Dec 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Sep 2025) to 22.00 Cr., marking an increase of 7.00 Cr..
For EPS in Rs, as of Dec 2025, the value is 25.32. The value appears strong and on an upward trend. It has increased from 17.14 (Sep 2025) to 25.32, marking an increase of 8.18.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 12:46 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	22	19	17	16	23	23	29	227	81	62	74	96	129
Expenses	21	18	16	14	18	16	20	77	44	33	41	46	73
Operating Profit	1	1	2	3	5	7	9	150	37	29	33	50	56
OPM %	6%	7%	9%	16%	23%	31%	32%	66%	46%	47%	44%	52%	44%
Other Income	0	0	0	0	0	1	2	3	7	7	13	15	20
Interest	1	1	1	1	1	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	1	1	1	1	1	1	1	2
Profit before tax	0	0	0	1	5	7	10	152	43	35	44	64	75
Tax %	14%	23%	23%	19%	24%	25%	23%	25%	26%	27%	28%	25%
Net Profit	0	0	0	1	3	5	8	114	32	26	32	48	58
EPS in Rs	0.59	0.36	0.51	1.76	5.35	8.18	10.24	151.66	42.89	34.55	37.40	55.57	66.92
Dividend Payout %	0%	0%	0%	17%	9%	6%	7%	6%	24%	8%	8%	7%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	200.00%	66.67%	60.00%	1325.00%	-71.93%	-18.75%	23.08%	50.00%
Change in YoY Net Profit Growth (%)	0.00%	-133.33%	-6.67%	1265.00%	-1396.93%	53.18%	41.83%	26.92%

3B Blackbio DX Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	18%
5 Years:	27%
3 Years:	6%
TTM:	25%

Compounded Profit Growth
10 Years:	70%
5 Years:	44%
3 Years:	14%
TTM:	34%

Stock Price CAGR
10 Years:	71%
5 Years:	32%
3 Years:	57%
1 Year:	-3%

Return on Equity
10 Years:	29%
5 Years:	30%
3 Years:	17%
Last Year:	19%

Last Updated: September 5, 2025, 1:56 pm

Balance Sheet

Last Updated: December 4, 2025, 2:15 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	6	6	6	6	6	6	7	7	7	9	9	9	9
Reserves	4	4	4	5	12	16	25	125	146	185	214	260	290
Borrowings	7	8	8	9	6	6	4	2	3	2	1	0	0
Other Liabilities	7	7	6	6	6	8	9	59	37	19	24	27	42
Total Liabilities	24	25	24	26	30	36	45	194	192	214	248	296	341
Fixed Assets	4	4	3	3	4	4	4	5	7	8	7	7	17
CWIP	0	0	0	0	0	0	0	0	0	0	0	0	0
Investments	0	0	0	0	0	0	1	59	93	92	117	156	160
Other Assets	20	21	21	22	26	32	40	130	93	114	123	132	163
Total Assets	24	25	24	26	30	36	45	194	192	214	248	296	341

Below is a detailed analysis of the balance sheet data for 3B Blackbio DX Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
For Reserves, as of Sep 2025, the value is 290.00 Cr.. The value appears strong and on an upward trend. It has increased from 260.00 Cr. (Mar 2025) to 290.00 Cr., marking an increase of 30.00 Cr..
For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 42.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 27.00 Cr. (Mar 2025) to 42.00 Cr., marking an increase of 15.00 Cr..
For Total Liabilities, as of Sep 2025, the value is 341.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 296.00 Cr. (Mar 2025) to 341.00 Cr., marking an increase of 45.00 Cr..
For Fixed Assets, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 10.00 Cr..
For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
For Investments, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 156.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 4.00 Cr..
For Other Assets, as of Sep 2025, the value is 163.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Mar 2025) to 163.00 Cr., marking an increase of 31.00 Cr..
For Total Assets, as of Sep 2025, the value is 341.00 Cr.. The value appears strong and on an upward trend. It has increased from 296.00 Cr. (Mar 2025) to 341.00 Cr., marking an increase of 45.00 Cr..

Notably, the Reserves (290.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	0	0	1	1	2	4	7	98	37	20	27	43
Cash from Investing Activity +	-0	-0	-0	-0	-1	-1	-1	-70	-28	15	-20	-33
Cash from Financing Activity +	0	-0	-1	-0	0	-1	1	-2	-15	-5	-4	-3
Net Cash Flow	0	-0	0	0	1	2	7	26	-6	30	3	7

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-6.00	-7.00	-6.00	-6.00	-1.00	1.00	5.00	148.00	34.00	27.00	32.00	50.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	213	262	283	321	259	290	252	56	136	200	179	138
Inventory Days	120	145	143	175						164	141	124
Days Payable	189	218	203	186						69	66	28
Cash Conversion Cycle	144	188	223	310	259	290	252	56	136	296	253	235
Working Capital Days	144	175	205	247	253	287	275	65	162	241	215	169
ROCE %	7%	7%	7%	13%	24%	28%	31%	162%	27%	19%	21%	26%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	38.43%	38.43%	38.43%	38.43%	41.29%	41.28%	41.28%	41.28%	41.28%	41.28%	41.28%	41.27%
FIIs	2.54%	3.06%	3.16%	3.38%	2.97%	3.28%	3.27%	2.68%	2.49%	2.70%	2.64%	2.57%
DIIs	0.00%	0.00%	0.82%	1.18%	1.89%	1.96%	1.96%	1.74%	1.60%	1.76%	1.82%	1.87%
Public	59.02%	58.50%	57.60%	56.99%	53.85%	53.48%	53.48%	54.29%	54.64%	54.28%	54.26%	54.27%
No. of Shareholders	13,136	12,416	10,513	10,088	9,753	9,399	9,586	10,166	10,345	10,619	10,709	10,507

Shareholding Pattern Chart

No. of Shareholders

3B Blackbio DX Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	55.57	37.40	34.55	43.40	151.66
Diluted EPS (Rs.)	55.57	37.40	34.55	43.40	151.66
Cash EPS (Rs.)	56.93	38.70	35.77	43.88	152.82
Book Value[Excl.RevalReserv]/Share (Rs.)	313.27	263.15	261.50	229.69	197.92
Book Value[Incl.RevalReserv]/Share (Rs.)	313.27	263.15	261.50	229.69	197.92
Revenue From Operations / Share (Rs.)	112.59	86.51	82.54	107.65	302.66
PBDIT / Share (Rs.)	76.08	53.12	48.55	58.73	204.07
PBIT / Share (Rs.)	74.82	51.88	47.40	57.84	203.25
PBT / Share (Rs.)	74.69	51.74	47.13	57.69	202.94
Net Profit / Share (Rs.)	55.66	37.46	34.62	42.98	152.00
NP After MI And SOA / Share (Rs.)	55.66	37.46	34.62	42.98	152.00
PBDIT Margin (%)	67.57	61.40	58.81	54.56	67.42
PBIT Margin (%)	66.45	59.97	57.42	53.72	67.15
PBT Margin (%)	66.34	59.80	57.10	53.59	67.05
Net Profit Margin (%)	49.43	43.30	41.94	39.92	50.21
NP After MI And SOA Margin (%)	49.43	43.30	41.94	39.92	50.21
Return on Networth / Equity (%)	17.76	14.39	15.14	21.04	86.23
Return on Capital Employeed (%)	23.13	19.28	17.76	24.73	101.13
Return On Assets (%)	16.12	12.93	12.11	16.76	58.83
Long Term Debt / Equity (X)	0.00	0.00	0.01	0.01	0.01
Total Debt / Equity (X)	0.00	0.00	0.01	0.01	0.01
Asset Turnover Ratio (%)	0.35	0.32	0.30	0.13	0.38
Current Ratio (X)	7.11	7.04	8.05	4.82	2.76
Quick Ratio (X)	6.64	6.56	7.49	4.38	2.64
Inventory Turnover Ratio (X)	11.24	2.41	2.33	2.66	2.68
Interest Coverage Ratio (X)	600.85	365.87	183.32	413.58	669.53
Interest Coverage Ratio (Post Tax) (X)	440.55	259.05	131.73	303.65	499.68
Enterprise Value (Cr.)	1319.35	600.55	278.94	248.35	196.43
EV / Net Operating Revenue (X)	13.68	8.10	4.51	3.08	0.86
EV / EBITDA (X)	20.24	13.19	7.67	5.64	1.28
MarketCap / Net Operating Revenue (X)	14.36	8.90	5.04	3.17	0.94
Price / BV (X)	5.16	2.96	1.82	1.67	1.62
Price / Net Operating Revenue (X)	14.36	8.90	5.04	3.17	0.94
EarningsYield	0.03	0.04	0.08	0.12	0.53

After reviewing the key financial ratios for 3B Blackbio DX Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 55.57. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.57, marking an increase of 18.17.
For Diluted EPS (Rs.), as of Mar 25, the value is 55.57. This value is within the healthy range. It has increased from 37.40 (Mar 24) to 55.57, marking an increase of 18.17.
For Cash EPS (Rs.), as of Mar 25, the value is 56.93. This value is within the healthy range. It has increased from 38.70 (Mar 24) to 56.93, marking an increase of 18.23.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 313.27. It has increased from 263.15 (Mar 24) to 313.27, marking an increase of 50.12.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 112.59. It has increased from 86.51 (Mar 24) to 112.59, marking an increase of 26.08.
For PBDIT / Share (Rs.), as of Mar 25, the value is 76.08. This value is within the healthy range. It has increased from 53.12 (Mar 24) to 76.08, marking an increase of 22.96.
For PBIT / Share (Rs.), as of Mar 25, the value is 74.82. This value is within the healthy range. It has increased from 51.88 (Mar 24) to 74.82, marking an increase of 22.94.
For PBT / Share (Rs.), as of Mar 25, the value is 74.69. This value is within the healthy range. It has increased from 51.74 (Mar 24) to 74.69, marking an increase of 22.95.
For Net Profit / Share (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.66, marking an increase of 18.20.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 55.66. This value is within the healthy range. It has increased from 37.46 (Mar 24) to 55.66, marking an increase of 18.20.
For PBDIT Margin (%), as of Mar 25, the value is 67.57. This value is within the healthy range. It has increased from 61.40 (Mar 24) to 67.57, marking an increase of 6.17.
For PBIT Margin (%), as of Mar 25, the value is 66.45. This value exceeds the healthy maximum of 20. It has increased from 59.97 (Mar 24) to 66.45, marking an increase of 6.48.
For PBT Margin (%), as of Mar 25, the value is 66.34. This value is within the healthy range. It has increased from 59.80 (Mar 24) to 66.34, marking an increase of 6.54.
For Net Profit Margin (%), as of Mar 25, the value is 49.43. This value exceeds the healthy maximum of 10. It has increased from 43.30 (Mar 24) to 49.43, marking an increase of 6.13.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 49.43. This value exceeds the healthy maximum of 20. It has increased from 43.30 (Mar 24) to 49.43, marking an increase of 6.13.
For Return on Networth / Equity (%), as of Mar 25, the value is 17.76. This value is within the healthy range. It has increased from 14.39 (Mar 24) to 17.76, marking an increase of 3.37.
For Return on Capital Employeed (%), as of Mar 25, the value is 23.13. This value is within the healthy range. It has increased from 19.28 (Mar 24) to 23.13, marking an increase of 3.85.
For Return On Assets (%), as of Mar 25, the value is 16.12. This value is within the healthy range. It has increased from 12.93 (Mar 24) to 16.12, marking an increase of 3.19.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.35. It has increased from 0.32 (Mar 24) to 0.35, marking an increase of 0.03.
For Current Ratio (X), as of Mar 25, the value is 7.11. This value exceeds the healthy maximum of 3. It has increased from 7.04 (Mar 24) to 7.11, marking an increase of 0.07.
For Quick Ratio (X), as of Mar 25, the value is 6.64. This value exceeds the healthy maximum of 2. It has increased from 6.56 (Mar 24) to 6.64, marking an increase of 0.08.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.24. This value exceeds the healthy maximum of 8. It has increased from 2.41 (Mar 24) to 11.24, marking an increase of 8.83.
For Interest Coverage Ratio (X), as of Mar 25, the value is 600.85. This value is within the healthy range. It has increased from 365.87 (Mar 24) to 600.85, marking an increase of 234.98.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 440.55. This value is within the healthy range. It has increased from 259.05 (Mar 24) to 440.55, marking an increase of 181.50.
For Enterprise Value (Cr.), as of Mar 25, the value is 1,319.35. It has increased from 600.55 (Mar 24) to 1,319.35, marking an increase of 718.80.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.68. This value exceeds the healthy maximum of 3. It has increased from 8.10 (Mar 24) to 13.68, marking an increase of 5.58.
For EV / EBITDA (X), as of Mar 25, the value is 20.24. This value exceeds the healthy maximum of 15. It has increased from 13.19 (Mar 24) to 20.24, marking an increase of 7.05.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 2.96 (Mar 24) to 5.16, marking an increase of 2.20.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.36. This value exceeds the healthy maximum of 3. It has increased from 8.90 (Mar 24) to 14.36, marking an increase of 5.46.
For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of 3B Blackbio DX Ltd as of March 10, 2026 is: ₹1,010.30

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 10, 2026, 3B Blackbio DX Ltd is Overvalued by 19.37% compared to the current share price ₹1,253.00

Intrinsic Value of 3B Blackbio DX Ltd as of March 10, 2026 is: ₹1,104.31

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 10, 2026, 3B Blackbio DX Ltd is Overvalued by 11.87% compared to the current share price ₹1,253.00

Last 5 Year EPS CAGR: 9.30%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 31.00%, which is a positive sign. The company has higher reserves (99.23 cr) compared to borrowings (4.31 cr), indicating strong financial stability. The company has shown consistent growth in sales (62.92 cr) and profit (33.54 cr) over the years.	The stock has a high average Working Capital Days of 203.17, which may not be favorable. The stock has a high average Cash Conversion Cycle of 220.17, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in 3B Blackbio DX Ltd:
1. Net Profit Margin: 49.43%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 23.13% (Industry Average ROCE: 15.21%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 17.76% (Industry Average ROE: 19.87%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 440.55
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 6.64
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 18.7 (Industry average Stock P/E: 26.51)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

3B BlackBio Dx Ltd. is a Public Limited Listed company incorporated on 27/05/1972 and has its registered office in the State of Madhya Pradesh, India. Company's Corporate Identification Number(CIN) is L24211MP1972PLC001131 and registration number is 001131. Currently Company is involved in the business activities of Manufacture of pesticides and other agrochemical products. Company's Total Operating Revenue is Rs. 90.53 Cr. and Equity Capital is Rs. 8.57 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Agro Chemicals/Pesticides	7-C, Industrial Area, Bhopal Madhya Pradesh 462023	Contact not found

Management
Name	Position Held
Mr. Dhirendra Dubey	Chairman & Managing Director
Mr. N K Dubey	Whole Time Director
Mr. Harihar Prasad Thapak	Independent Director
Mr. Abdul Moin Khan	Independent Director
Mrs. Mithala Dubey	Director
Mr. Vivek Saihgal	Additional Director

FAQ

What is the intrinsic value of 3B Blackbio DX Ltd?

3B Blackbio DX Ltd's intrinsic value (as of 10 March 2026) is ₹1104.31 which is 11.87% lower the current market price of ₹1,253.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,076 Cr. market cap, FY2025-2026 high/low of ₹2,020/1,151, reserves of ₹290 Cr, and liabilities of ₹341 Cr.

What is the Market Cap of 3B Blackbio DX Ltd?

The Market Cap of 3B Blackbio DX Ltd is 1,076 Cr..

What is the current Stock Price of 3B Blackbio DX Ltd as on 10 March 2026?

The current stock price of 3B Blackbio DX Ltd as on 10 March 2026 is ₹1,253.

What is the High / Low of 3B Blackbio DX Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of 3B Blackbio DX Ltd stocks is ₹2,020/1,151.

What is the Stock P/E of 3B Blackbio DX Ltd?

The Stock P/E of 3B Blackbio DX Ltd is 18.7.

What is the Book Value of 3B Blackbio DX Ltd?

The Book Value of 3B Blackbio DX Ltd is 347.

What is the Dividend Yield of 3B Blackbio DX Ltd?

The Dividend Yield of 3B Blackbio DX Ltd is 0.32 %.

What is the ROCE of 3B Blackbio DX Ltd?

The ROCE of 3B Blackbio DX Ltd is 25.8 %.

What is the ROE of 3B Blackbio DX Ltd?

The ROE of 3B Blackbio DX Ltd is 19.4 %.

What is the Face Value of 3B Blackbio DX Ltd?

The Face Value of 3B Blackbio DX Ltd is 10.0.